---
trial_id: 321
discovery_date: 2022-04-02 17:30:16.045026
date: 2022-04-02 17:30:16.045026
title: "Effect of MD1003 in spinal progressive multiple sclerosis: a pivotal randomized double blind placebo controlled study"
summary: |
  <p>EudraCT Number: 2013-002113-35<br />Sponsor Protocol Number: MD1003CT2013-02MS-SPI<br />Sponsor Name: MEDDAY SAS<br />Start Date: Information not available in EudraCT<br />Medical condition: Progressive spinal multiple sclerosis<br />Disease: <br />Version: 18.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10053395<br />Term: Progressive multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002113-35/FR">FR</a> (Completed)</p>
link: 'https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-002113-35'
published_date: NaT
trial_source: Clinical Trials Register Europe
relevant: 
options:
  unlisted: false
---
<p>EudraCT Number: 2013-002113-35<br />Sponsor Protocol Number: MD1003CT2013-02MS-SPI<br />Sponsor Name: MEDDAY SAS<br />Start Date: Information not available in EudraCT<br />Medical condition: Progressive spinal multiple sclerosis<br />Disease: <br />Version: 18.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10053395<br />Term: Progressive multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002113-35/FR">FR</a> (Completed)</p>